PATIENTS WITH SYSTEMIC SCLEROSIS ASSOCIATING OTHER AUTOIMMUNE DISEASES HAVE A MILDER DISEASE COURSE
Authors:   EUSTAR centre 100, Internal Medicine and Rheumatology Department,  Dr. I. Cantacuzino Hospital, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania, Soare Alina , Pintilie Simona ,   EUSTAR centre 100, Internal Medicine and Rheumatology Department,  Dr. I. Cantacuzino Hospital, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania, Gherghe Ana Maria ,   EUSTAR centre 100, Internal Medicine and Rheumatology Department,  Dr. I. Cantacuzino Hospital, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania, Radu Alexandra ,   EUSTAR centre 100, Internal Medicine and Rheumatology Department,  Dr. I. Cantacuzino Hospital, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania, Dobrota Rucsandra ,   EUSTAR centre 100, Internal Medicine and Rheumatology Department,  Dr. I. Cantacuzino Hospital, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania, Sasu Mariana ,   EUSTAR centre 100, Internal Medicine and Rheumatology Department,  Dr. I. Cantacuzino Hospital, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania, Bojinca Mihai ,   EUSTAR centre 100, Internal Medicine and Rheumatology Department,  Dr. I. Cantacuzino Hospital, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania, Stoica Victor ,   EUSTAR centre 100, Internal Medicine and Rheumatology Department,  Dr. I. Cantacuzino Hospital, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania, Mihai Carina ,   EUSTAR centre 100, Internal Medicine and Rheumatology Department,  Dr. I. Cantacuzino Hospital, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania
Published: September 2021

Background and objectives. Systemic sclerosis (SSc) is a multisystem connective tissue disease (CTD), being one of the most heterogeneous diseases of the spectrum of CTDs. It may associate other autoimmune diseases (AIDs), therefore in this study we aimed to evaluate the prevalence of other AIDs in a cohort of patients with SSc and to evaluate their prognosis in comparison to patients with SSc without this association. Patients and methods. We performed a retrospective study in patients with SSc satisfying the ACR 1980 or the ACR/EULAR 2013 criteria, who were evaluated between January 2005 and May 2014 in our SSc center. These patients were investigated according to the EUSTAR recommendations, including modified Rodnan Skin Score (mRSS), lung function tests (LFT), echocardiography etc. As a control group for evaluating the prevalence of the AIDs we used all patients with Rheumatoid Arthritis (RA) visiting our clinic between January-December 2005. Data of all RA patients were collected from the electronic database of the hospital. All AIDs mentioned in the discharge diagnoses were recorded. Between-group comparisons were made with the chi-square test for nominal variables and with the independent-sample t-test for numeric variables. Results. 144 patients with SSc were included: 88.8% females, 66.6% with the limited cutaneous subset of disease (lcSSc), mean age 53.9 ± 12.8 years, mean disease duration at study enrollment 5.1±10.5 years and a mean follow-up time of 3.7 ± 2.6 years. Prevalence of the AID in the SSc cohort was 19.4%, patients with lcSSc being more prone to associate other AID (p = 0.001). We noted a tendency towards less interstitial lung disease (p = 0.056) and less digital ulcers (p = 0.081) in patients with SSc and AIDs. Comparing skin involvement for each year of follow-up in patients with SSc with and without and AIDs we observed that the first tended to have lower and more stable values of the mRSS. Conclusion. Patients with SSc and AIDs tend to have a better outcome than the ones without this association. mRSS remains stable across the years in patients with SSc and AID, with lower values than the SSc patients.